Wolverine Trading, LLC Cassava Sciences Inc Put Options Transaction History

Wolverine Trading, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$18.44 - $26.41 $497,880 - $713,070	27,000 New	27,000 $547,000
Q3 2023 Nov 15, 2023	BUY	$16.64 - $25.32 $221,312 - $336,756	13,300 Added 28.98%	59,200 $985,000
Q2 2023 Aug 23, 2023	BUY	$21.59 - $27.88 $166,243 - $214,676	7,700 Added 20.16%	45,900 $1.13 Million
Q1 2023 May 15, 2023	SELL	$23.46 - $36.44 $143,106 - $222,284	-6,100 Reduced 13.77%	38,200 $917,000
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $1.23 Million - $1.96 Million	44,300 New	44,300 $1.31 Million

Q2 2022 Aug 15, 2022	SELL	$17.22 - $38.47 $55,104 - $123,104	-3,200 Reduced 4.88%	62,400 $1.86 Million
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $417,280 - $679,040	-12,800 Reduced 16.33%	65,600 $2.53 Million
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $2.18 Million - $5.38 Million	-59,200 Reduced 43.02%	78,400 $3.43 Million
Q3 2021 Nov 12, 2021	BUY	$41.79 - $135.3 $3.55 Million - $11.5 Million	84,900 Added 161.1%	137,600 $8.55 Million
Q2 2021 Aug 06, 2021	BUY	$32.15 - $89.72 $160,750 - $448,600	5,000 Added 10.48%	52,700 $4.37 Million
Q1 2021 May 14, 2021	BUY	$7.09 - $87.95 $338,193 - $4.2 Million	47,700 New	47,700 $2.1 Million

172

11.3M

1.61M

1.43M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $410M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.